Volume 3.06 | Feb 17

Prostate Cell News 3.06 February 17, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases
To determine the role of telomere dysfunction and telomerase reactivation in generating pro-oncogenic genomic events and in carcinoma progression, an inducible telomerase reverse transcriptase allele was crossed onto a prostate cancer-prone mouse model null for Pten and p53 tumor suppressors. [Cell] Abstract

New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

IRX4 at 5p15 Suppresses Prostate Cancer Growth through the Interaction with Vitamin D Receptor, Conferring Prostate Cancer Susceptibility
In this study, researchers found knockdown of IRX4 prostate cancer (PC) cells enhanced their growth and IRX4 overexpression in PC cells suppressed their growth, indicating the functional association of IRX4 with PC and its tumor suppressive effect. [Hum Mol Genet] Abstract

The SRA Protein UHRF1 Promotes Epigenetic Crosstalks and Is Involved in Prostate Cancer Progression
Here, scientists report that UHRF1 is frequently over expressed in human prostate tumors and has an important role in prostate cancer pathogenesis and progression. [Oncogene] Abstract

Androgen Receptor Exon 1 Mutation Causes Androgen Insensitivity by Creating a Phosphorylation Site and Inhibiting Melanoma Antigen-A11 Activation of N/C Interaction-Dependent Transactivation
In this report researchers investigate the functional defect associated with an androgen receptor exon 1 missense mutation R405S that caused partial androgen insensitivity. [J Biol Chem] Abstract

Acid Ceramidase-Mediated Production of Sphingosine 1-Phosphate Promotes Prostate Cancer Invasion through Up-Regulation of Cathepsin B
Here investigators demonstrate that acid ceramidase, through generation of sphingosine-1-phosphate, promotes Ets1 nuclear expression and binding to the promoter region of matrix-degrading protease cathepsin B. [Int J Cancer] Abstract

Cell-to-Cell Signaling Influences the Fate of Prostate Cancer Stem Cells and Their Potential to Generate More Aggressive Tumors
To address whether tumor aggressiveness is driven by cancer stem cells (CSC) and by what extent this property may be relevant within the tumor mass, scientists isolated a rare tumor cell population on the basis of its CD44+CD24 phenotype from the human androgen-independent prostate carcinoma cell line DU145 and established its CSC properties. [PLoS One] Abstract

CXCR4 Expression in Prostate Cancer Progenitor Cells
Researchers show that the CXCR4/CXCL12 axis, a key regulator of tumor dissemination, plays a role in the maintenance of prostate cancer stem-like cells. [PLoS One] Abstract

Androgen-Induced Cell Migration: Role of Androgen Receptor/Filamin A Association
Researchers’ data indicates that the extra nuclear androgen receptor/filamin A/integrin beta 1 complex is the key by which androgen activates signaling leading to cell migration. [PLoS One] Abstract

CLINICAL RESEARCH

Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Allogeneic Prostate Cancer Cells and Ipilimumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Trial
Researchers aimed to assess the safety of combined treatment with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine and ipilimumab in patients with metastatic castration-resistant prostate cancer. [Lancet Oncol] Abstract

Ipilimumab and a Poxviral Vaccine Targeting Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Trial
Scientists aimed to assess the safety and tolerability of ipilimumab in combination with a poxviral-based vaccine targeting prostate-specific antigen and containing transgenes for T-cell co-stimulatory molecule expression, including CD80. [Lancet Oncol] Abstract

Does Local Recurrence of Prostate Cancer after Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI Study
The purpose of this study was to determine if local recurrence of prostate cancer after radiation therapy occurs at the same site as the primary tumor before treatment, using longitudinal magnetic resonance (MR) imaging and MR spectroscopic imaging to assess dominant tumor location. [Int J Radiat Oncol Biol Phys] Abstract

View Nature.com Webcast: Current Controversies - HIV Vaccines

INDUSTRY NEWS

FDA Approves Gen-Probe’s PROGENSA® PCA3 Assay, First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies
Gen-Probe announced that the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy. [Gen-Prove Incorporated] Press Release

MIT Team Promotes Prostate Cancer Prognosis Tool
A team competing in the Massachusetts Institute of Technology (MIT) $100,000 Entrepreneurship Competition is hoping to market a lab technique for analyzing biopsy tissue that will offer prognostic information that will be crucial when deciding between radical prostatectomy surgery or a more cautious approach. [Massachusetts Institute of Technology] Press Release

USC Institute of Urology Receives $13.3 Million Gift
University of Southern California (USC) president C. L. Max Nikias, announced an anonymous gift of $13.3 million that will fund the forthcoming USC Urology Robotics Center of Excellence and a program for prostate cancer targeting. [University of Southern California] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW Experimental Biology (EB) 2012 
April 21-25, 2012 
San Diego, United States 

NEW 3rd International Congress on Responsible Stem Cell Research (RSCR) 
April 25-28, 2012 
Vatican City, Rome 

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Scientist – Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Research Technologist (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)


Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

PhD Position – Cell Biology/Infection Research (University of Münster)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow (Louisiana State University Health Sciences Center) 


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us